- Home
- APVO vs CNSP Comparison
APVO vs CNSP Comparison
Compare APVO & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- CNSP
- Stock Information
- Founded
- APVO 2016
- CNSP 2017
- Country
- APVO United States
- CNSP United States
- Employees
- APVO N/A
- CNSP N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- CNSP Health Care
- Exchange
- APVO Nasdaq
- CNSP Nasdaq
- Market Cap
- APVO 4.1M
- CNSP 4.0M
- IPO Year
- APVO N/A
- CNSP 2019
- Fundamental
- Price
- APVO $2.01
- CNSP $5.11
- Analyst Decision
- APVO Strong Buy
- CNSP Hold
- Analyst Count
- APVO 1
- CNSP 1
- Target Price
- APVO $5,920.00
- CNSP N/A
- AVG Volume (30 Days)
- APVO 134.2K
- CNSP 40.3K
- Earning Date
- APVO 08-11-2025
- CNSP 08-14-2025
- Dividend Yield
- APVO N/A
- CNSP N/A
- EPS Growth
- APVO N/A
- CNSP N/A
- EPS
- APVO N/A
- CNSP N/A
- Revenue
- APVO N/A
- CNSP N/A
- Revenue This Year
- APVO N/A
- CNSP N/A
- Revenue Next Year
- APVO N/A
- CNSP N/A
- P/E Ratio
- APVO N/A
- CNSP N/A
- Revenue Growth
- APVO N/A
- CNSP N/A
- 52 Week Low
- APVO $1.72
- CNSP $4.93
- 52 Week High
- APVO $381.10
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- APVO 29.31
- CNSP 21.28
- Support Level
- APVO $1.72
- CNSP $6.28
- Resistance Level
- APVO $2.20
- CNSP $7.75
- Average True Range (ATR)
- APVO 0.18
- CNSP 0.78
- MACD
- APVO 0.01
- CNSP -0.13
- Stochastic Oscillator
- APVO 22.58
- CNSP 3.96
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.